Skip to content

Effects of Chronic Sleep Fragmentation on Brain Function and Tumor Immune Microenvironment in Patients with Colorectal Cancer: A Prospective Cohort Study

The Impact of Chronic Sleep Fragmentation on the Tumor Immune Microenvironment and Brain Function in Patients with Colorectal Cancer: A Prospective Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124571
Enrollment
Unknown
Registered
2026-05-14
Start date
2026-05-23
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer, sleep fragmentation

Interventions

Sleep Fragmentation Group:None

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with rectal adenocarcinoma confirmed by colonoscopy biopsy pathology, who have not received any neoadjuvant chemoradiotherapy, and plan to undergo elective radical surgery; 2. Tumor staging: Preoperative imaging evaluation (chest, abdominal, and pelvic CT/MRI, whole-body PET-CT) confirms no lymph node or distant metastasis (N0M0); 3. Age: 18-75 years old; 4. Gender: no restriction; 5. ASA classification I-III; 6. BMI less than 32 kg/m^2.

Exclusion criteria

Exclusion criteria: 1.Cardiovascular disorders: Patients with cardiac arrhythmias complicated with severe cardio-cerebrovascular diseases (including chronic heart failure, valvular abnormalities, myocardial infarction, recent cerebral infarction, etc.); 2.Respiratory disorders: Patients with dyspnea, respiratory failure, or pulmonary hypertension; 3.Neurocognitive impairment: Patients with mental illnesses or cognitive dysfunction who are unable to cooperate; 4.Other malignancies: Patients with a history of or current other malignant tumors under treatment; 5.MRI contraindications: Patients with absolute contraindications to MRI scanning (such as non-removable metal implants in the body, claustrophobia, etc.); 6.Inability to obtain informed consent: Patients unable to provide signed informed consent;

Design outcomes

Primary

MeasureTime frame
Density of CD8+ T cell infiltration in tumor tissue;

Secondary

MeasureTime frame
Percentage of CD8+ T cells in peripheral blood;

Countries

China

Contacts

Public ContactChanghong Miao

Zhongshan Hospital, Fudan University

miao.changhong@zs-hospital.sh.cn+86 21 6404 1990

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026